June 21, 2024
Company name:
Representative:

A l i v e x i s , I n c .
S. Roy Kimura, Ph.D., CEO

Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for
Cathepsin C Inhibitor Program MOD-A
News – June 21, 2024 - Alivexis, Inc. (headquartered in Tokyo, Japan, “Alivexis”) and
Melodia Therapeutics AG (headquartered in Basel, Switzerland, “Melodia”), a company
established by Forty51 Ventures, announced today that they have entered into an exclusive
license agreement for the worldwide development, manufacturing, and commercialization ofAlivexis' MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. MDI-0151 is aninnovative clinical candidate identified in Alivexis’ MOD-A discovery program.
Melodia will rapidly initiate IND-enabling activities for MDI-0151 to prepare for a Phase
1/Phase 2a study in various refractory inflammatory diseases caused by excessive activationof neutrophils, such as ANCA-associated Vasculitis and several other relevant diseases in
the context of neutrophils.

Patients suffering from these diseases have a high unmet

medical need.
Alivexis and Melodia will leverage their respective expertise in drug discovery researchand development with the aim of obtaining clinical Proof of Concept in these indications.
Under the terms of the agreement, Alivexis grants Melodia worldwide rights to develop,
manufacture, and commercialize MDI-0151 and will receive from Melodia an upfront payment
and development and sales milestone payments totaling up to approximately $275 million(JPY 42.7 billion 1), and will be entitled to receive royalties on net sales of any marketedproduct. In addition, Alivexis is eligible to receive a number of warrants to subscribe forMelodia's common shares.
S. Roy Kimura, Ph.D., CEO of Alivexis, commented on the deal: “I am pleased to announce

the signing of our licensing and clinical partnership with Melodia for our MOD-A Cathepsin C
inhibitor program. This event marks a significant milestone for Alivexis and serves asvalidation of our drug discovery R&D team and platform, our proprietary pipeline of discovery
programs, and our business model involving the use of our cutting-edge platform toaccelerate clinical candidate discovery for diseases with high unmet need. This is the first ofmany licensing and collaboration agreements that we anticipate from our maturing portfolioof IND-ready candidate molecules in our pipeline and our unique and proven discovery

1*USD/JPY conversion rate: 1551

platform. We are confident that the Melodia team will be able to take our candidate molecule
through clinical trials and ultimately help many patients in need suffering from chronic
inflammatory diseases.”
Melodia’s founding shareholder Forty51 Ventures commented on the deal: “We areextremely pleased to in-license and continue the development of MDI-0151. We consider
that this asset from Alivexis has best-in-class, blockbuster potential. Melodia aims to develop
the program in a variety of underserved indications in the field of immunology. Furtherannouncements will follow shortly as Melodia advances this program expeditiously.”
About MDI-0151
MDI-0151 is a clinical candidate compound from the Alivexis’ discovery program MOD-A,
focused on Cathepsin C inhibition. Cathepsin C, also known as dipeptidyl peptidase-1 (DPP1), is an enzyme responsible for the activation of a group of proteases that play an importantrole in the destruction of tissues by neutrophils. As inhibition of Cathepsin C is believed tohave little effect on the immune function of neutrophils, MDI-0151 may effectively treat
various immune and inflammatory diseases while not compromising the immune system.

About Alivexis, Inc.
Headquarter：Daiichi Hibiya Building 7F, Shimbashi 1-18-21, Minato-ku, Tokyo 105-0004, Japan
Representative directors: S. Roy Kimura, Ph.D., CEO / Kazuki Ohno, Dr. Eng. COO
Established: August 8, 2016
URL： https://alivexis.com
Business Description: A network-based drug discovery company utilizing cutting-edge
technologies.

About Melodia Therapeutics AG
Headquarter：Basel, Switzerland
Founding shareholder: Forty51 Advisors AG
Established: December 2023
URL： https://www.melodiatx.com
Business Description: A biotech company focused on developing therapies for neutrophil-driven
diseases.

Questions?
info@alivexis.com

2